Clinical Trial Update: To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of OBI-833/OBI-821 with first-line erlotinib in EGFR-mutant, Globo H-positive locally advanced or metastatic n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• OBI-821
• OBI-833

Snippet

Sponsor: OBI Pharma, Inc | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING